Story

Silence Therapeutics Stock Surges 16% Ahead of Key Divesiran Trial Data

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Silence Therapeutics Stock Surges 16% Ahead of Key Divesiran Trial Data
Text size
Background

Shares of Silence Therapeutics (NASDAQ: SLN) surged in pre-market trading Monday as investors anticipated the release of crucial mid-stage trial data for its lead drug candidate, divesiran. The biotechnology company's stock climbed 16.2% ahead of a scheduled conference call to discuss the results.

Key Catalyst: Divesiran Data Readout

Silence Therapeutics announced over the weekend it would hold a conference call and webcast at 8:00 a.m. EDT on Monday to discuss topline results from its Phase 2 SANRECO trial. The trial evaluates divesiran, an siRNA therapeutic, for the treatment of polycythemia vera (PV), a rare blood disorder.

Management has previously described this data release as a "defining milestone" for the company. The event is considered the most significant near-term catalyst, heightening investor focus on the outcome of the clinical study.

High Expectations for SANRECO Trial

Investor optimism heading into the data release was underpinned by strong results from the drug's Phase 1 trial. That earlier study showed that the number of required phlebotomy procedures (blood withdrawals) for participants fell from 80 in the six months prior to treatment to just 5 during the active treatment period.

Sample IUX Markets – In-articleAd

The Phase 2 SANRECO study is a 48-patient, randomized, double-blind, placebo-controlled trial. Its primary endpoint measures the proportion of patients who can maintain a hematocrit level below 45% without needing phlebotomies between weeks 18 and 36 of the study.

Market Context and Regulatory Status

Divesiran's potential has already been recognized by regulators, with the U.S. Food and Drug Administration granting it both Fast Track and Orphan Drug designations. These designations can help expedite the drug's development and review process.

The significant stock movement was company-specific, occurring against a relatively neutral market backdrop where the S&P 500 and NASDAQ saw only minor gains. The surge positions the data readout as a potential transformative event for the clinical-stage biotechnology firm.

Read next

More on Stocks
Back to latest news

LATEST